POSC160 Economic Evaluation of Using Ribociclib in HER2- Negative Breast Cancer Patients: A Systematic Review of Evidence

Abstract

Authors

W Alotaibi M Alhamdan B Balkhi

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×